Abstract
Follow-up after cystectomy for carcinoma of the bladder requires special considerations. Patients must be monitored for "new" urothelial tumors, followed for a local pelvic recurrence or distant metastasis of the original primary cancer, and monitored for sequelae from the urinary diversion. Additional urothelial tumors may be amenable to salvage therapy if identified at an early stage. This is particularly true for a urethral carcinoma identified by urethral washing. Metastatic disease may be better palliated by earlier detection. The frequency of metabolic complications after either continent cutaneous or orthotopic urinary diversion may not be defined precisely at this time and lifelong follow-up will be necessary.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
